| Differential impact of tamoxifen and aromatase inhibitors on thrombin generation: the prospective HEMOBREAST cohort | Blood advances |  | | 2022 | 296 | 686 |
|
| Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab | Gynecologic Oncology Reports | | | 2021 | 272 | 163 |
|
| Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss | Cancer Biology and Therapy | | | 2020 | 363 | 234 |
|
